A pharmacovigilance survey based on the FAERS database found that the most common, high mortality adverse reactions to BTK inhibitors (ibrutinib and acatinib) were infections, such as pneumonia and pleural effusions, especially in elderly patients. Here, BTK is linked to pneumonia.